Emerging biotech boosts Worldwide Healthcare trust performance

NAV up 2.5%

Japanese pharmaceutical and emerging biotechnology stocks were two key areas pushing the Worldwide Healthcare trust’s returns, according to its results.

The group published its unaudited six-month results up to 30 September today (23 November), revealing how healthcare stocks have acted more defensively amid macroeconomic volatility. The results showed the trust made 3.1% total return during the period, a turnaround from its 5.8% loss recorded in the previous half year report. This return was ahead of the MSCI World Healthcare Index benchmark's 2.1%. But according to the report, it was not a straightforward journey to outperformance. The company said the returns had not "been linear" as the first two months of the reporting period wer...